**Core Concept**
Omalizumab is a recombinant humanized monoclonal antibody that targets the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the release of histamine and other mediators involved in allergic reactions.

**Why the Correct Answer is Right**
Omalizumab binds to IgE, reducing its levels and subsequently decreasing the activation of mast cells and basophils. This mechanism makes it an effective treatment for severe allergic asthma and chronic spontaneous urticaria. The drug is administered subcutaneously every 2-4 weeks, and its efficacy is monitored by measuring IgE levels and clinical symptoms.

**Why Each Wrong Option is Incorrect**
**Option A:** Omalizumab is not primarily used for the treatment of atopic dermatitis.
**Option B:** While omalizumab may have some effects on anaphylaxis, it is not the primary treatment for acute anaphylaxis.
**Option C:** Omalizumab is not used for the treatment of autoimmune disorders like rheumatoid arthritis or lupus.

**Clinical Pearl / High-Yield Fact**
Omalizumab is a biologic medication that requires regular monitoring of IgE levels and clinical symptoms to adjust dosing and optimize efficacy.

**Correct Answer:** D. Severe allergic asthma and chronic spontaneous urticaria.